• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗与年龄相关的多种疾病:药物发现的挑战。

Treating age-related multimorbidity: the drug discovery challenge.

机构信息

MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.

Drug Discovery Unit, University of Dundee, Dundee, UK.

出版信息

Drug Discov Today. 2020 Aug;25(8):1403-1415. doi: 10.1016/j.drudis.2020.06.016. Epub 2020 Jun 20.

DOI:10.1016/j.drudis.2020.06.016
PMID:32574698
Abstract

Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.

摘要

高龄是多种疾病的主要危险因素。目前的临床实践针对与年龄相关的个体疾病进行治疗,导致了多种药物的使用。因此,针对导致衰老的生物学过程可能既可以预防多种疾病,也可以预防多种药物的使用。

相似文献

1
Treating age-related multimorbidity: the drug discovery challenge.治疗与年龄相关的多种疾病:药物发现的挑战。
Drug Discov Today. 2020 Aug;25(8):1403-1415. doi: 10.1016/j.drudis.2020.06.016. Epub 2020 Jun 20.
2
Integrative GWAS and co-localisation analysis suggests novel genes associated with age-related multimorbidity.整合全基因组关联研究和共定位分析提示与年龄相关的多种疾病相关的新基因。
Sci Data. 2023 Sep 25;10(1):655. doi: 10.1038/s41597-023-02513-4.
3
Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy.概念化共病和多病患者的多种药物使用:超越术语“多药治疗”的标准定义建议。
J Clin Epidemiol. 2019 Feb;106:98-107. doi: 10.1016/j.jclinepi.2018.10.014. Epub 2018 Oct 29.
4
Molecular Morbidity Score-Can MicroRNAs Assess the Burden of Disease?分子发病评分——微小 RNA 可评估疾病负担吗?
Int J Mol Sci. 2024 Jul 24;25(15):8042. doi: 10.3390/ijms25158042.
5
Multimorbidity patterns, polypharmacy and their association with liver and kidney abnormalities in people over 65 years of age: a longitudinal study.65 岁以上人群的多种合并症模式、多种药物治疗及其与肝肾功能异常的关系:一项纵向研究。
BMC Geriatr. 2020 Jun 12;20(1):206. doi: 10.1186/s12877-020-01580-1.
6
The use of geroprotectors to prevent multimorbidity: Opportunities and challenges.使用 geroprotectors 预防多种疾病:机遇与挑战。
Mech Ageing Dev. 2021 Jan;193:111391. doi: 10.1016/j.mad.2020.111391. Epub 2020 Nov 2.
7
Multimorbidity patterns in chronic older patients, potentially inappropriate prescribing and adverse drug reactions: protocol of the multicentre prospective cohort study MoPIM.慢性病老年患者的多病共存模式、潜在不适当处方和药物不良反应:多中心前瞻性队列研究 MoPIM 的方案。
BMJ Open. 2020 Jan 26;10(1):e033322. doi: 10.1136/bmjopen-2019-033322.
8
Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways.多种疾病共存与功能障碍——双向相互作用、协同效应和共同途径。
J Intern Med. 2019 Mar;285(3):255-271. doi: 10.1111/joim.12843. Epub 2018 Nov 22.
9
The co-occurrence of multimorbidity and polypharmacy among middle-aged and older adults in Canada: A cross-sectional study using the Canadian Longitudinal Study on Aging (CLSA) and the Canadian Primary Care Sentinel Surveillance Network (CPCSSN).加拿大中老年人多重疾病与多种药物联合使用的共存情况:一项使用加拿大老龄化纵向研究(CLSA)和加拿大初级保健哨兵监测网络(CPCSSN)的横断面研究。
PLoS One. 2025 Jan 15;20(1):e0312873. doi: 10.1371/journal.pone.0312873. eCollection 2025.
10
Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis.慢性病与药物在青年和成年人群中的共病模式和多药联用:使用因子分析研究慢性疾病与药物之间的系统关联。
PLoS One. 2019 Feb 6;14(2):e0210701. doi: 10.1371/journal.pone.0210701. eCollection 2019.

引用本文的文献

1
Using primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adults.利用原始数据和常规收集的数据确定中国农村地区的多病共存患病率及模式:一项对6474名中国成年人的代表性横断面研究
Lancet Reg Health West Pac. 2024 Dec 26;54:101272. doi: 10.1016/j.lanwpc.2024.101272. eCollection 2025 Jan.
2
Molecular Morbidity Score-Can MicroRNAs Assess the Burden of Disease?分子发病评分——微小 RNA 可评估疾病负担吗?
Int J Mol Sci. 2024 Jul 24;25(15):8042. doi: 10.3390/ijms25158042.
3
Accelerated aging of skeletal muscle and the immune system in patients with chronic liver disease.
慢性肝病患者骨骼肌和免疫系统的加速老化。
Exp Mol Med. 2024 Jul;56(7):1667-1681. doi: 10.1038/s12276-024-01287-y. Epub 2024 Jul 18.
4
Integrative GWAS and co-localisation analysis suggests novel genes associated with age-related multimorbidity.整合全基因组关联研究和共定位分析提示与年龄相关的多种疾病相关的新基因。
Sci Data. 2023 Sep 25;10(1):655. doi: 10.1038/s41597-023-02513-4.
5
Multimorbidity and polypharmacy in hospitalized older patients: a cross-sectional study.住院老年患者的多病共存和多种药物治疗:一项横断面研究。
BMC Geriatr. 2023 Jul 11;23(1):423. doi: 10.1186/s12877-023-04109-4.
6
Cluster analysis for the overall health status of elderly, multimorbid patients with diabetes.老年、多病共存糖尿病患者整体健康状况的聚类分析。
Front Public Health. 2023 Apr 4;11:1031457. doi: 10.3389/fpubh.2023.1031457. eCollection 2023.
7
UKRI MRC National Musculoskeletal Ageing Network: strategic prioritisation to increase healthy lifespan and minimise physical frailty.英国研究与创新署医学研究理事会国家肌肉骨骼衰老网络:增加健康寿命并将身体虚弱降至最低的战略优先事项。
Arch Osteoporos. 2022 Nov 21;17(1):147. doi: 10.1007/s11657-022-01172-z.
8
The association between multimorbidity and mobility disability-free life expectancy in adults aged 85 years and over: A modelling study in the Newcastle 85+ cohort.85 岁及以上成年人多病共存与无移动性残疾预期寿命之间的关联:纽卡斯尔 85+队列的建模研究。
PLoS Med. 2022 Nov 14;19(11):e1004130. doi: 10.1371/journal.pmed.1004130. eCollection 2022 Nov.
9
Advances in the roles and mechanisms of lignans against Alzheimer's disease.木脂素在抗阿尔茨海默病中的作用及机制研究进展
Front Pharmacol. 2022 Oct 12;13:960112. doi: 10.3389/fphar.2022.960112. eCollection 2022.
10
Comorbidity phenotypes and risk of mortality in patients with osteoarthritis in the UK: a latent class analysis.英国骨关节炎患者的合并症表型与死亡率风险:一项潜在类别分析。
Arthritis Res Ther. 2022 Oct 13;24(1):231. doi: 10.1186/s13075-022-02909-4.